ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm
Publication
, Conference
Moriarty, PM; Thompson, PD; Cannon, CP; Guyton, JR; Bergeron, J; Zieve, FJ; Bruckert, E; Jacobson, TA; Baccara-Dinet, MT; Zhao, J; Pordy, R; Gipe, D
Published in: CIRCULATION
December 2, 2014
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
December 2, 2014
Volume
130
Issue
23
Start / End Page
2108 / 2109
Location
Chicago, IL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
Scientific Sessions of the American-Heart-Association and American-Stroke-Association / Resuscitation Science Symposium
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., … Gipe, D. (2014). ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm. In CIRCULATION (Vol. 130, pp. 2108–2109). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
Moriarty, Patrick M., Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron, Franklin J. Zieve, Eric Bruckert, et al. “ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm.” In CIRCULATION, 130:2108–9. LIPPINCOTT WILLIAMS & WILKINS, 2014.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2014. p. 2108–9.
Moriarty, Patrick M., et al. “ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm.” CIRCULATION, vol. 130, no. 23, LIPPINCOTT WILLIAMS & WILKINS, 2014, pp. 2108–09.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Pordy R, Gipe D. ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2014. p. 2108–2109.
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
December 2, 2014
Volume
130
Issue
23
Start / End Page
2108 / 2109
Location
Chicago, IL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
Scientific Sessions of the American-Heart-Association and American-Stroke-Association / Resuscitation Science Symposium
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology